J&J launches enhanced VARIPULSE Pro PFA device in Europe [developing]
Key Questions
What is the VARIPULSE Pro device?
The VARIPULSE Pro is an enhanced pulsed field ablation (PFA) system launched by Johnson & Johnson for treating atrial fibrillation (AFib). It represents a significant upgrade in J&J's PFA portfolio.
Where and when was the VARIPULSE Pro launched?
Johnson & Johnson launched the VARIPULSE Pro in Europe following CE Mark approval, as announced recently. This marks a key milestone in the European market.
What are the key improvements in the VARIPULSE Pro?
The device enables 5x faster ablations, operates at lower temperatures, integrates with Carto3, and is backed by VARIPURE EHRA data. These enhancements improve efficiency and safety for AFib treatments.
How does the VARIPULSE Pro launch impact J&J's market position?
The launch bolsters Johnson & Johnson's MedTech Electrophysiology (EP) portfolio against competitors like Boston Scientific and Medtronic. It advances their PFA offerings in Europe.
What are the next steps for the VARIPULSE Pro?
A US launch is anticipated following the European rollout. Monitoring adoption and sales will provide insights into its broader impact.
VARIPULSE Pro upgrade CE Mark Europe launch confirmed: 5x faster ablations, lower temps, Carto3 integration, VARIPURE EHRA data; advances PFA portfolio; bolsters MedTech EP vs BSX/MDT; US next? Monitor adoption/sales.